CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

Launched by GERMAN CANCER RESEARCH CENTER · Dec 7, 2022

Keywords

ClinConnect Summary

The CATCH trial is studying how to use genetic information to improve treatment for patients with metastatic breast cancer, which is breast cancer that has spread to other parts of the body. The main goal is to find specific markers in patients' tumors that can help doctors choose the best targeted therapies for their individual cases. This means that instead of a one-size-fits-all approach, treatments can be tailored to the unique characteristics of each patient's cancer.

To participate in the trial, you need to be at least 18 years old and diagnosed with advanced or metastatic breast cancer, regardless of the specific type or how many treatments you have already received. During the trial, doctors will collect samples from your cancer and blood to analyze them for genetic information. This will help identify potential treatments that might work best for you. The trial is currently recruiting participants, and it's important to know that if you decide to join, you will be contributing to valuable research that aims to improve future therapies for breast cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Female and male breast cancer patients ≥ 18 or if the legal guardian has agreed to the respective informed consent form (ICF)
• • Patients with advanced or metastatic breast cancer (irrespective of clinical parameters such as TNM, subgroups, therapy lines)
• • Patients, who agreed to and were able to sign the informed consent form.
• Exclusion Criteria:
• • Early breast cancer
• • Inability to take a tissue bioptic sample due to reasons such as physical location of the lesion or health of the patient
• • Any physical or mental handicap or severe comorbidities that would hamper the adequate cooperation with the patient.

Trial Officials